# EDGAR Filing Document

**Accession Number:** 0001760854
**File Stem:** 0001171843-23-000961
**Filing Date:** 2023-2
**Character Count:** 5749
**Document Hash:** 9dbcfd73889dea4c499ebdf242d17903
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-000961.hdr.sgml**: 20230214

**ACCESSION NUMBER**: 0001171843-23-000961

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230214

**FILED AS OF DATE**: 20230214

**DATE AS OF CHANGE**: 20230214

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Nanobiotix S.A.
- **CENTRAL INDEX KEY:** 0001760854
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** I0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39777
- **FILM NUMBER:** 23629475

**BUSINESS ADDRESS:**
- **STREET 1:** 60 RUE DE WATTIGNIES
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75012
- **BUSINESS PHONE:** 33140260470

**MAIL ADDRESS:**
- **STREET 1:** 60 RUE DE WATTIGNIES
- **CITY:** PARIS
- **STATE:** I0
- **ZIP:** 75012

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2023**

Commission File Number: **001-39777**

**Nanobiotix S.A.**

(Translation of registrant's name into English)

**60 Rue de Wattignies 75012 Paris, France**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ ]

------

On February 14, 2023, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

[(c) Exhibit 99.1. Press release dated February 14, 2023](exh_991.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | <u>**&nbsp;&nbsp;&nbsp;&nbsp;Nanobiotix S.A.&nbsp;&nbsp;&nbsp;&nbsp;**</u> |
|  | (Registrant) |
| Date: February 14, 2023 | <u>&nbsp;&nbsp;&nbsp;&nbsp;/s/ Bart Van Rhijn&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  | Bart Van Rhijn |
|  | Chief Financial Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Voting Rights and Shares Capital of the Company**

**In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)**

PARIS, Feb. 14, 2023 (GLOBE NEWSWIRE) --

Market: Euronext Paris / Nasdaq

Euronext Compartment: B

ISIN code: FR0011341205

Nasdaq: NBTX

Bloomberg: NANO:FP

Reuters: NANO.PA

Website: www.nanobiotix.com

---

| | | | |
|:---|:---|:---|:---|
| **Date** | **Number of Shares<br>Outstanding** | **Total number of voting rights** | **Total number of voting rights** |
| **Date** | **Number of Shares<br>Outstanding** | **Total voting rights,<br>theoretical<sup>1</sup>** | **Total voting rights,**<br>**exercisable<sup>2</sup>** |
| January 31, 2023<br>| 34875872 | 36286976 | 36264858 |

---

According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix's capital if those figures differ from the information previously disclosed.

**About NANOBIOTIX**

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.

For more information about Nanobiotix, visit us at <u>www.nanobiotix.com</u> or follow us on <u>LinkedIn</u> and <u>Twitter</u>.

__________________________________

<sup>1</sup> *The total number of theoretical (or "gross") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.*

<sup>2</sup> *The total number of exercisable at a Shareholders' Meeting (or "net") voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.*

**Contacts**

---

| | |
|:---|:---|
| *Nanobiotix* | *Nanobiotix* |
| **<br>Nanobiotix Communications**<br>*Brandon Owens*<br>*VP, Communications*<br>+1 (617) 852-4835<br><u>contact@nanobiotix.com</u><br>| **<br>Nanobiotix Investor Relations** <br>*Kate McNeil*<br>*SVP, Investor Relations*<br>+1 (609) 678-7388<br><u>investors@nanobiotix.com</u><br>|
| *Media Relations* | *Media Relations* |
| <br>France – **Ulysse Communication** <br>Pierre-Louis Germain<br>+ 33 (0) 6 64 79 97 51 <br>plgermain@ulysse-communication.com <br>| <br>**LifeSci Advisors** <br>*Ligia Vela-Reid* <br>+44 (0) 7413825310 <br><u>lvela-reid@lifesciadvisors.com</u><br>|

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Attachment**

* 2023-02-14 -- NBTX -- Voting Rights -- FINAL (https://ml.globenewswire.com/Resource/Download/36de8c06-9b18-4f34-856f-19dbf977fa14)